Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit in Grade 2 IDH1/2-mutant glioma after surgery, including among patients originally assigned to placebo who later crossed over to treatment.
The crossover data carry real weight, with limits
By the January 17, 2025 cutoff, 144 of the 163 placebo-assigned patients had crossed over to vorasidenib. Their median investigator-assessed progression-free survival was 37.2 months overall. That is not a trivial number in a slow-moving, life-altering disease where delaying progression and postponing more burdensome interventions can matter enormously to patients and families.
The histology split is also encouraging. Median progression-free survival was 37.2 months among crossover patients with astrocytoma, while it was not reached for those with oligodendroglioma. Patients who had already progressed at crossover posted a 33.4-month median; it was not reached among those without progression at crossover. Those are useful directional results, though nobody should pretend a post-crossover analysis has the pristine comparability of the original randomized treatment period. Once patients switch therapies, selection and timing complicate the picture. That is just how these studies work.
Still, the tumor-volume finding is hard to shrug off. Average tumor volume had risen 16.1% per six months before crossover and then fell 2.9% per six months afterward. The pattern appeared in both major histologic subgroups. It does not settle every clinical question, but it supports the biological premise that IDH inhibition is doing meaningful work rather than merely polishing a statistical endpoint.
Responses improved as time passed
The blinded independent review committee objective response rate for the overall population climbed from 10.7% in September 2022 to 20.8% in January 2025. Astrocytoma rose from 7.5% to 17.5%, while oligodendroglioma moved from 13.6% to 23.9%. One reported confidence interval for the earlier oligodendroglioma figure appears internally awkward in the presentation materials, so it deserves verification rather than blind repetition. The broader trend, however, is plain enough: responses accumulated with follow-up.
That matters because this drug is not being judged solely on whether a scan changes quickly. In lower-grade IDH-mutant glioma, the more consequential question can be whether treatment buys patients time with disease control while preserving day-to-day functioning. That is a higher bar than a flashy short-term response rate, and frankly it should be.
Seizures and quality of life are not side notes
The exploratory seizure and quality-of-life analysis may be the most human part of this update. Among patients with at least one seizure at baseline or during treatment, the seizure-rate ratio versus placebo improved to 0.28 at the January 2025 cutoff, compared with 0.36 at an earlier cutoff. The reported vorasidenib seizure rate declined from 18.2 to 15.9 seizures per person-year.
There is a strange-looking detail in the release: it says the proportion of treated patients with on-treatment seizures was 98.1% and then 98.2%. That wording does not square neatly with the favorable seizure-rate narrative and needs context from the full abstract or investigators. Good sector analysis means saying that out loud, not sweeping odd figures under the rug because the rest of the deck is upbeat.
Quality-of-life findings were exploratory, not a final verdict, but they pointed in the right direction. Vorasidenib was associated with lower risk of worsening on the FACT-Br measure, with a hazard ratio of 0.38, and on its brain-cancer subscale, with a hazard ratio of 0.32. For a brain tumor population, maintaining cognition, function, and independence is not decorative data. It is part of the treatment outcome.
Liver monitoring remains the practical trade-off
Extended follow-up found no new safety signals and no treatment-related deaths, which is reassuring. It does not mean the safety discussion disappears. Grade 3 or higher treatment-emergent adverse events occurred in 31.7% of patients randomized to VORANIGO and 20.1% of crossover patients. Elevated liver enzymes were the most common serious-grade events: alanine aminotransferase increases occurred in 10.8% and 7.6%, respectively.
Discontinuations were uncommon, at 4.8% in the original treatment group and 2.1% after crossover, but liver-function monitoring remains a concrete part of care. Patients should discuss individual risks, reproductive considerations, medication interactions, and monitoring with their treating clinicians rather than treating conference data as personal medical guidance.
Servier is governed by a nonprofit foundation, so this is not a conventional public-equity story with a ticker flashing on a terminal. Yet the sector implication is substantial. The company says it commits close to 20% of brand-name medicine revenue to research and development, and this kind of long-term evidence strengthens the case for mutation-defined cancer care. INDIGO is not the end of the argument. It is a meaningful, increasingly mature piece of evidence that vorasidenib may help manage this disease over time without sacrificing the outcomes patients feel every day.